[CGEN] Compugen Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.25 Change: 0.1 (1.94%)
Ext. hours: Change: 0 (0%)

chart CGEN

Refresh chart

Strongest Trends Summary For CGEN

CGEN is in the medium-term up 58% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company?s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities72.13 M Cash From Investing Activities-64.09 M Cash From Operating Activities-11.15 M Gross Profit130 K
Net Profit-6.14 M Operating Profit-6.32 M Total Assets108.48 M Total Current Assets68.55 M
Total Current Liabilities5.24 M Total Debt Total Liabilities7.52 M Total Revenue510 K
Technical Data
High 52 week4.49 Low 52 week2.78 Last close4.12 Last change2.74%
RSI48.86 Average true range0.2 Beta0.72 Volume73.51 K
Simple moving average 20 days-1.87% Simple moving average 50 days3.44% Simple moving average 200 days13.86%
Performance Data
Performance Week-0.48% Performance Month-2.6% Performance Quart15.73% Performance Half11.96%
Performance Year4.3% Performance Year-to-date35.53% Volatility daily2.67% Volatility weekly5.96%
Volatility monthly12.22% Volatility yearly42.33% Relative Volume296.09% Average Volume206.53 K
New High New Low

News

2020-06-01 07:00:00 | Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® Nivolumab and TIGIT Inhibitor

2020-05-27 07:00:00 | Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort

2020-05-20 07:02:00 | 2 Top Biotech Picks for May

2020-05-18 08:46:12 | Is the Options Market Predicting a Spike in Compugen CGEN Stock?

2020-05-13 09:48:01 | How Compugen CGEN Stock Stands Out in a Strong Industry

2020-05-08 14:39:51 | We're Not Very Worried About Compugen's NASDAQ:CGEN Cash Burn Rate

2020-05-08 10:52:02 | Top Ranked Momentum Stocks to Buy for May 8th

2020-05-06 22:00:47 | Compugen Ltd. CGEN Q1 2020 Earnings Call Transcript

2020-05-06 07:00:00 | Compugen Reports First Quarter 2020 Results

2020-05-04 11:57:09 | Can This Biotech Shed New Light on Cancer Immunotherapies?

2020-04-30 12:00:04 | Top Ranked Momentum Stocks to Buy for April 30th

2020-04-30 12:00:04 | Compugen CGEN is a Great Momentum Stock: Should You Buy?

2020-04-30 12:00:04 | What Makes Compugen CGEN a New Strong Buy Stock

2020-04-27 06:05:00 | Compugen sees "encouraging signals" from early-stage cancer trial

2020-04-27 06:00:00 | Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting

2020-04-24 10:50:51 | 3 Monster Growth Stocks Gearing up for Gains

2020-04-23 07:00:00 | Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020

2020-04-22 08:22:00 | Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent

2020-04-20 07:00:00 | Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research

2020-04-14 07:00:00 | Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting

2020-04-06 07:00:00 | Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies

2020-03-17 07:00:00 | Compugen Announces Closing of $75 Million Public Offering of Ordinary Shares

2020-03-12 06:05:00 | Compugen Announces Pricing of $75 Million Public Offering of Ordinary Shares

2020-03-11 16:01:00 | Compugen Announces Commencement of Public Offering of Ordinary Shares

2020-03-10 10:00:02 | Company News for Mar 10, 2020

2020-03-09 07:10:00 | Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study

2020-02-20 07:05:00 | Compugen Reports Fourth Quarter and Full Year 2019 Results

2020-02-20 07:00:00 | Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® Nivolumab and TIGIT Inhibitor

2020-02-10 07:58:47 | Should You Worry About Compugen Ltd.'s NASDAQ:CGEN CEO Pay Cheque?

2020-02-10 07:00:00 | Compugen to Release Fourth Quarter and Full Year 2019 Results on Thursday, February 20, 2020

2020-02-07 07:00:00 | Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-oncology Symposium

2020-02-04 07:00:00 | Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies

2020-01-29 08:30:00 | Compugen Further Expands Intellectual Property Portfolio With New European Patent for Anti-PVRIG Antibodies

2020-01-16 19:47:18 | Compugen Stock Rebounds After Analyst Sees 60% Upside

2020-01-09 07:00:00 | Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones

2020-01-08 07:00:00 | Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development

2019-12-23 20:04:37 | Did Hedge Funds Drop The Ball On Compugen Ltd. CGEN ?

2019-12-20 07:00:00 | Compugen Added to the NASDAQ Biotechnology Index

2019-12-17 08:38:01 | 5 Biotech Stocks That Have More Than Doubled This Year

2019-12-12 11:56:15 | The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

2019-12-12 11:35:07 | Janpix, Inc. Announces Appointment of Sanford Sandy Zweifach as Executive Chairman to its Board of Directors

2019-12-11 09:04:02 | 5 Biotech Stocks Up More Than 100% This Year So Far

2019-12-11 05:31:08 | Compugen NASDAQ:CGEN Shareholders Have Enjoyed A 76% Share Price Gain

2019-12-03 12:00:05 | Are You Looking for a Top Momentum Pick? Why Compugen CGEN is a Great Choice

2019-11-11 07:00:00 | Compugen Reports Third Quarter 2019 Results

2019-11-06 08:30:00 | Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

2019-11-05 08:06:00 | Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

2019-11-05 08:05:00 | Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

2019-11-04 07:00:00 | Compugen Announces FDA Clearance of IND Application for COM902

2019-10-28 07:00:00 | Compugen to Release Third Quarter 2019 Results on Monday, November 11, 2019